Hans Knapp
Co-Founder and General Partner @ Yaletown Partners
Vancouver, Canada
Hans Knapp is a Series A investor at Yaletown Partners in Vancouver focused on Software and Health Care. Hans co-founded Yaletown Venture Partners and brings over 15 years of legal counsel, corporate governance, turn-around, and investing experience to the Yaletown team. Hans manages Yaletown's investment in Redlen Technologies, Equicare Health, Genologics, Thetus, and Mixpo. In addition, as Yaletown's General Counselhe directs ourfirm's investment transactions, operations and legal affairs. Prior to Yaletown, Hans was Vice President of Investments and Corporate Counsel for Brigill Investments, a private Vancouver-based venture capital firm. Earlier in his career he practiced law in the commercial litigation group of Borden Ladner Gervais and held a judicial clerkship at British Columbia's highest court, the BC Court of Appeal. A recipient of Business in Vancouver's "Top 40 Under 40" award, Hans has B.A. and LLB degrees from the University of British Columbia and is called to the Bar of British Columbia.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Hans Knapp invests in
Stages Hans Knapp invests in
Countries Hans Knapp invests in
Round sizes
Round size
- Seed
- $603k–$1M
- Series A
- $4.5M–$16M
Investment Focus
Industry
- Software 5 (71%)
- Health Care 2 (29%)
- Industrial Automation 2 (29%)
- SaaS 1 (14%)
- AgTech 1 (14%)
Stage
- Series A 3 (43%)
- Seed 1 (14%)
- Angel 1 (14%)
- Series C 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nanoprecise Sci Corp
|
Nanoprecise Sci Corp is an automated AI-based predictive maintenance solution provider that facilitates early detection of even small changes in machine operations well before they impact production or cause downtime. Nanoprecise specializes in the implementation of Artificial Intelligence and IIoT technology for predictive asset maintenance andreducing the carbon footprint of manufacturing plants. We are defining the industry’s service standard for the monitoring & analytics of all types of industrial machines, through our leading energy efficiency & health analytics platform for industrial assets. We work with companies across various sectors to help drive their Industry 4.0 journey. | $38M / Series C / Mar 27, 2025 | |
Elevated Signals
|
Elevated Signals builds manufacturing operations software for regulated industries like cannabis, nutraceuticals, food, and beverage. As an alternative to rigid ERPs and fragile spreadsheets, its GMP-ready platform connects inventory, quality & compliance, planning, and costing into one easy-to-use system - empowering teams to plan smarter, actfaster, and scale with confidence.Purpose-built for complex, fast-growing operations, the platform supports vertically integrated producers, white-label and co-manufacturers, and GMP-ready, export-focused facilities that need airtight traceability and flexibility. It's used across teams: operations and QA capture production floor data in real time, while finance, compliance, sales, and planning rely on it for informed decision-making and audit readiness.It provides:- Real-time visibility into materials and processes - Embedded quality assurance and compliance - A structured but adaptable system that supports how manufacturers actually workFeatures available:- Inventory Management - Work Orders & Production Tracking - SKU & Product Management - Vendor & Procurement Management - Production Planning (New Module) - Embedded Quality Assurance (QA) - Traceability & Compliance - Role-Based Access & Permissions - Reporting & Export Tools | $5.8M / Series A / Feb 27, 2024 | |
ePACT Network
|
ePACT will improve emergency preparedness across North America. By connecting every home and organization with shared information and resources, ePACT will have a positive impact on the safety of our communities. Its benefits will encourage users to adopt and share the system, while its tools help North Americans manage unexpected situations. | $4.5M / Series A / Aug 30, 2019 | |
Circle Cardiovascular Imaging
|
Circle Cardiovascular Imaging develops and markets cardiovascular post-processing software for the evaluation of magnetic resonance imaging (MRI) and CT images. It offers cmr42, a cardiovascular post-processing software for viewing and analyzing cardiovascular MR (CMR) images; ct42, a cardiovascular post-processing software for viewing andanalyzing CCT images; cvi42, an integrated cardiovascular post-processing software for viewing and analyzing CMR and CCT images; and report42, a software solution that facilitates the documentation and reporting of CMR and CCT images. Circle Cardiovascular Imaging also provides product support, and training and education services for its software. Its software is used in the treatment of various indications, including heart failure, coronary artery disease, ischemic heart disease, myocardial infarction/scar, non-ischemic CM, myocarditis, valvular heart disease, cardiac masses, pericardial disease, pulmonary angiography, atrial fibrillation, carotid disease, and thoracic aortic disease. Its software is used by physicians and healthcare institutions in clinical and research settings. Circle Cardiovascular Imaging markets its software through a network of distributors worldwide. Kelly Cherniwchan founded it in 2007, with its headquarters in Calgary in Canada. | $16M / Series A / May 15, 2018 | |
|
ePACT Network
|
ePACT will improve emergency preparedness across North America. By connecting every home and organization with shared information and resources, ePACT will have a positive impact on the safety of our communities. Its benefits will encourage users to adopt and share the system, while its tools help North Americans manage unexpected situations. | $1M / Seed / Feb 19, 2014 | |
|
ePACT Network
|
ePACT will improve emergency preparedness across North America. By connecting every home and organization with shared information and resources, ePACT will have a positive impact on the safety of our communities. Its benefits will encourage users to adopt and share the system, while its tools help North Americans manage unexpected situations. | $603K / Seed / Jan 11, 2013 | |
VitaminLab
|
VitaminLab takes your health history, our nutrient testing or health data, and uses our matching algorithm to create an all-in-one personalized supplement that impacts your health. The company, run by a team of pharmacists and health care professionals, was founded to change the status quo of the supplement industry. | Angel |
Co-Investors
About Yaletown Partners
Yaletown Partners specializes in investing in software, data, and device technologies. It invests in technology companies that improve industry and enterprise productivity and sustainability, to help accelerate their growth, shorten exit timeframes, and accomplish strong exit premiums.With offices in Vancouver, Calgary, Montréal, and a growingpresence in Toronto, Yaletown is led by a national team that contributes almost 100 years of technology-industry experience and a network of extensive industry relationships.
Yaletown Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brad Johns
General Partner
|
|||
|
Hans Knapp
Co-Founder and General Partner
|
|||
Michael Sfalcin
Principal
|
|||
Salil Munjal
General Partner
|
|||
Brad Zumwalt
Special Limited Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Hans Knapp invest in?
Hans Knapp invests primarily in Software, Health Care and Industrial Automation startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Hans Knapp's check size?
Hans Knapp typically joins rounds of $603k–$1M at Seed and $4.5M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hans Knapp participates in.
When did Hans Knapp last invest?
The most recent investment recorded for Hans Knapp closed in Mar 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
